Paula Rodríguez‐Otero

Research interests

Publications

• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

  Nature Reviews Clinical Oncology · 2025 · https://doi.org/10.1038/s41571-025-01041-x

• International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00043-3

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2312054

• Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00159-6

• Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02528-9

• Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2213614

• Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

  Blood · 2022 · https://doi.org/10.1182/blood.2022015526

• Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2204591

• LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

  Leukemia · 2022 · https://doi.org/10.1038/s41375-022-01531-2

• Roadmap to cure multiple myeloma

  Cancer Treatment Reviews · 2021 · https://doi.org/10.1016/j.ctrv.2021.102284

• Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

  Blood · 2021 · https://doi.org/10.1182/blood-2021-147983

• Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.02259

• Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

  Blood · 2020 · https://doi.org/10.1182/blood.2019004537

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

  Blood · 2019 · https://doi.org/10.1182/blood.2019000722

• Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30788-0

• First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

  Blood · 2019 · https://doi.org/10.1182/blood-2019-122895

• A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

  Leukemia · 2019 · https://doi.org/10.1038/s41375-019-0539-0

• The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-18-1597

• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

  The Lancet Haematology · 2019 · https://doi.org/10.1016/s2352-3026(19)30110-3

• Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

  Blood Cancer Journal · 2018 · https://doi.org/10.1038/s41408-018-0153-9

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

  Blood · 2014 · https://doi.org/10.1182/blood-2014-03-560540

• Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.19.3441

• Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia

  Cancer Research · 2009 · https://doi.org/10.1158/0008-5472.can-08-4025

Current projects

No projects listed.